Skip to content

Comparison of ovulation induction in patients with polycystic ovary syndrome of different doses of letrozole combined with human menopausal gonadotropin:a randomized controlled trial

Comparison of ovulation induction in patients with polycystic ovary syndrome of different doses of letrozole combined with human menopausal gonadotropin:a randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045832
Enrollment
Unknown
Registered
2021-04-25
Start date
2021-05-10
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Group A:2.5mg letrozole
Group B:5.0mg letrozole

Sponsors

Union Hospital,Tongji Medical College,Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. PCOS patients who meet the 2003 Rotterdam diagnostic criteria: (1) The patient has sparse ovulation or even anovulation; (2) The patient's clinical symptoms or biochemical manifestations show hyperandrogenemia; (3) Abdominal color Doppler ultrasound shows polycystic changes in the ovaries (vaginal color Doppler ultrasound shows that the number of follicles containing 2-9 mm in one or even both sides of the ovaries is greater than 12); The diagnosis can be made if two of the above three criteria are met. 2. Younger than 40 years old, no abnormal sexual life, infertility course not less than 1 year; 3. Hysterosalpingography shows that the uterus is normal, and at least one fallopian tube is unobstructed; 4. The results of spouse's sperm analysis are no abnormal or mildly low and asthenospermia; 5. The function of various organs is normal, without any endocrine diseases such as hypopituitarism, hyperthyroidism, etc.

Exclusion criteria

Exclusion criteria: 1. Those who are known to be allergic to related drugs; 2. Combined with mental or neurological diseases, unable to actively cooperate with the test; 3. Previously suffering from abnormal diseases of the uterus or uterine cavity; 4. Past exposure to teratogenic toxins, radiation, etc.

Design outcomes

Primary

MeasureTime frame
Ovulation rate;Total pregnancy rate;Clinical pregnancy rate;

Secondary

MeasureTime frame
Singleton pregnancy rate;Multiple pregnancy rate;Ectopic pregnancy rate;Early pregnancy loss rate;Number of patients;Number of cycles;

Countries

China

Contacts

Public ContactLiu Yi

Union Hospital,Tongji Medical College,Huazhong University of Science and Technology

liqun94@163.com+86 13971038710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026